Wilmington Savings Fund Society FSB Buys Shares of 45,714 Kenvue Inc. (NYSE:KVUE)

Wilmington Savings Fund Society FSB purchased a new position in shares of Kenvue Inc. (NYSE:KVUE) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 45,714 shares of the company’s stock, valued at approximately $1,057,000.

A number of other hedge funds and other institutional investors have also modified their holdings of KVUE. Riverview Trust Co bought a new stake in Kenvue during the third quarter worth approximately $30,000. Ashton Thomas Securities LLC bought a new stake in shares of Kenvue during the 3rd quarter worth $35,000. Deseret Mutual Benefit Administrators grew its stake in Kenvue by 49.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after buying an additional 651 shares during the last quarter. Studio Investment Management LLC raised its holdings in Kenvue by 52.1% in the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after acquiring an additional 845 shares during the period. Finally, Brooklyn Investment Group acquired a new position in Kenvue during the 3rd quarter worth $71,000. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KVUE. Barclays raised Kenvue to a “hold” rating in a research report on Thursday. Piper Sandler lifted their price target on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday, September 23rd. JPMorgan Chase & Co. increased their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Jefferies Financial Group initiated coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the company from $25.00 to $24.00 in a report on Thursday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $22.64.

Kenvue Stock Down 0.5 %

Shares of NYSE:KVUE opened at $22.21 on Friday. The company has a market capitalization of $42.58 billion, a PE ratio of 40.38, a P/E/G ratio of 2.02 and a beta of 1.36. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company’s fifty day moving average is $22.95 and its 200-day moving average is $21.20. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company’s revenue was down .4% on a year-over-year basis. During the same quarter last year, the business posted $0.31 earnings per share. Equities research analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.69%. The ex-dividend date of this dividend was Wednesday, November 13th. Kenvue’s dividend payout ratio is currently 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.